AbbVie (ABBV) Return on Capital Employed (2013 - 2026)
AbbVie (ABBV) posted quarterly Return on Capital Employed of 16.47% for Q1 2026, up 632.0% year-over-year from 2.25% in Q1 2025, and down 0.99% quarter-over-quarter from 16.63% in Q4 2025.
AbbVie (ABBV) Return on Capital Employed (2013 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Return on Capital Employed for 14 consecutive years, with 16.47% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 632.0% year-over-year to 16.47%; the TTM figure through Mar 2026 stood at 16.47% (up 632.0% YoY), while the FY2025 annual figure was 16.52%, up 702.0% from the prior year.
- Return on Capital Employed declined to 16.47% in Q1 2026 per ABBV's latest filing, from 16.63% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 16.93% in Q2 2023 and bottomed at 9.09% in Q4 2024.
- Historically, Return on Capital Employed has averaged 13.9% across 5 years, with a median of 14.82% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 507 bps — and 2025, when it jumped 754 bps.
- AbbVie's Return on Capital Employed stood at 16.39% in 2022, then declined by 20 bps to 13.07% in 2023, then plunged by 30 bps to 9.09% in 2024, then surged by 83 bps to 16.63% in 2025, then fell by 1 bps to 16.47% in 2026.
- Business Quant data shows ABBV's Return on Capital Employed at 16.47% in Q1 2026, 16.63% in Q4 2025, and 9.4% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 79.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.92% |
| Mar 31, 2026 | 16.47% |
| Dec 31, 2025 | 16.63% |
| Sep 30, 2025 | 9.40% |
| Jun 30, 2025 | 11.32% |
| Mar 31, 2025 | 10.15% |
| Dec 31, 2024 | 9.09% |
| Sep 30, 2024 | 13.88% |
| Jun 30, 2024 | 11.86% |
| Mar 31, 2024 | 12.75% |
| Dec 31, 2023 | 13.07% |
| Sep 30, 2023 | 14.91% |
| Jun 30, 2023 | 16.93% |
| Mar 31, 2023 | 14.82% |
| Dec 31, 2022 | 16.39% |
| Sep 30, 2022 | 16.15% |
| Jun 30, 2022 | 16.00% |
| Mar 31, 2022 | 16.50% |
| Dec 31, 2021 | 15.93% |
| Sep 30, 2021 | 13.85% |